XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.52

-22.9%

Dec 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (15990)	8/16/2002 4:36:20 PM
From: aknahow	Read Replies (1) of 17367

AH & H has a post call report out that does contain fresh insights, if not fresh news. The projected timing of income from Raptiva was moved up, due to the Serono agreement. The report continues to show a new indication for Neuprex by Baxter before year end. The call itself created doubt by the lack of any mention of Neuprex or BPI until a question was asked about Neuprex. The expansion of the Crohn's trial mentioned, in passing yesterday, was new news. The problem is that individual investors are probably unable to understand the implications as well as institutional investors. It was a very small trial of only 42 subjects. Xoma did not inform listeners of the expansion details. Would they extend the trial if Neuprex not working? Does expanding mean it is working or that the efficacy was week and adding more was required to bolster the results?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next